Biocon Biologics in Covid-19 antibody deal; Byju's mopping up smaller rivals; the promise of India's SaaS companies

Biocon Biologics, a fully integrated biosimilars company and a subsidiary of Biocon, has won an exclusive license from US-based Adagio Therapeutics to manufacture and commercialise an antibody treatment for Covid-19, based on the American company's ADG20 monoclonal antibody, for India and some emerging markets. Byju's is mopping up smaller competitors; and in today's tech conversation, Venkatesh Peddi at Chiratae Ventures and Praveen Bhadada at Zinnov explain how Indian cloud software companies will get to $1 trillion in value